Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer

Clinical Cancer Research

Volumn 16, Issue 19, 2010, Pages 4832-4842

  Wittenburg, Luke A ^a   Gustafson, Daniel L ^a,b   Thamm, Douglas H ^a,b  

^a Department of Ecosystem Science and Sustainability   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; DOXORUBICIN; HISTONE; VALPROATE SEMISODIUM;

ADENOCARCINOMA; ALKALINE PHOSPHATASE BLOOD LEVEL; ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; APOCRINE GLAND ADENOCARCINOMA; APPETITE DISORDER; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER TISSUE; CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; CYTOCHEMISTRY; DIARRHEA; DOG; DRUG ACETYLATION; DRUG DETERMINATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; EVENING DOSAGE; FEBRILE NEUTROPENIA; FEMALE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LETHARGY; LOADING DRUG DOSE; LYMPHOMA; MALE; MELANOMA; METABOLIC DISORDER; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PRIORITY JOURNAL; SOFT TISSUE CANCER; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMATOGRAPHY, LIQUID; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HISTONE DEACETYLASE INHIBITORS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; VALPROIC ACID;

EID: 77957580176     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1238     Document Type: Article

References (44)

1. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007;1:19-25.
2. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53.
3. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5:455-63. (Pubitemid 38610247)
4. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev 2001; 1:194-202. (Pubitemid 33741894)
5. McIntyre J, Angels-Moral M, Bozzo J. Combination therapy with valproic acid in cancer: initial clinical approach. Drugs Future 2007;32:1.
6. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 2005;4:1993-2000.
7. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291-300. (Pubitemid 37413470)
8. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578-88.
9. Gilbert J, Gore SD, Herman JG, Carducci MA. The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 2004;10:4589-96. (Pubitemid 38955507)
10. Karagiannis TC, El-Osta A. Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer. Epigenetics 2006;1: 121-6.
11. Jaboin J, Wild J, Hamidi H, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002;62:6108-15. (Pubitemid 35244459)
12. Woo HJ, Lee SJ, Choi BT, Park YM, Choi YH. Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Exp Mol Pathol 2007;82:77-84. (Pubitemid 46038263)
13. Mai A, Massa S, Rotili D, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005;25: 261-309. (Pubitemid 40489663)
14. Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25:1979-85. (Pubitemid 46972780)
15. Munster P, Marchion D, Bicaku E, et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009;15:2488-96.
16. Gordon I, Paoloni M, Mazcko C, Khanna C. The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med 2009;6:e1000161.
17. Khanna C, London C, Vail D, Mazcko C, Hirschfeld S. Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clin Cancer Res 2009;15:5671-7.
18. Paoloni MC, Tandle A, Mazcko C, et al. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFα to cancer vasculature. PloS One 2009;4:e4972.
19. Kimmelman J, Nalbantoglu J. Faithful companions: a proposal for neurooncology trials in pet dogs. Cancer Res 2007;67:4541-4. (Pubitemid 46910154)
20. Hansen K, Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 2004;40:858-80. (Pubitemid 38519765)
21. Kisseberth WC, Murahari S, London CA, Kulp SK, Chen CS. Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines. Am J Vet Res 2008;69:938-45.
22. Wittenburg L, Bisson L, Rose B, Thamm DH. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol 2010. DOI: 10.1007/s00280-010-1287-z. Epub ahead of print.
23. Schuchmann M, Schulze-Bergkamen H, Fleischer B, et al. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 2006;15:227-30.
24. Yamanegi K, Yamane J, Hata M, et al. Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death. J Cancer Res Clin Oncol 2009;135:879-89.
25. Das CM, Aguilera D, Vasquez H, et al. Valproic acid induces p21 and topoisomerase-II (α/β) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 2007;85:159-70. (Pubitemid 47629397)
26. Catalano MG, Fortunati N, Pugliese M, et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 2006;191:465-72.
27. Veterinary Co-operative Oncology Group. Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195-213.
28. Plumb DC. In: Plumb DC, editor. Plumb's veterinary drug handbook. 6th ed. Ames, Iowa: Blackwell Publishing; 2008, p. 916-8.
29. Wagner J. Noncompartmental and system analysis. Pharmacokinetics for the pharmaceutical scientist. Lancaster, PA: Technomic Publishing Company, Inc.; 1993, p. 83-99.
30. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
31. Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci 2002;91: 1488-501.
32. Selting KA, Ogilvie GK, Gustafson DL, et al. Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma. Am J Vet Res 2006;67:145-51.
33. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004;92:223-37.
34. de Bono JS, Kristeleit R, Tolcher A, et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 2008;14:6663-73.
35. Siu LL, Pili R, Duran I, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26:1940-7.
36. Ogilvie GK, Reynolds HA, Richardson RC, et al. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 1989;195:1580-3.
37. Daud AI, Dawson J, DeConti RC, et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 2009;15:2479-87.
38. Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 2000;60 Suppl 1:1-14, discussion 41-2.
39. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist 2002;7:401-9.
40. Jain RK, Lee JJ, Hong D, et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 2010;16:1289-97.
41. Hoekstra R, Verweij J, Eskens FA. Clinical trial design for target specific anticancer agents. Invest New Drugs 2003;21:243-50.
42. Silva MF, Ruiter JP, Overmars H, et al. Complete β-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. Biochem J 2002;362:755-60.
43. Vail D, MacEwen EG, Young KM. Canine lymphoma and lymphoid leukemias. In: Withrow SJ, MacEwen EG, editors. Small animal clinical oncology. 3rd Edition Philadelphia: W B. Saunders; 2001, p. 558-90.
44. Vail D, Withrow SJ. Tumors of the skin and subcutaneous tissues. In: Withrow SJ, MacEwen EG, editors. Small animal clinical oncology. 3rd ed. Philadelphia: W B. Saunders; 2001, p. 233-60.